UK health institute endorses cholinesterase inhibitors, such as Exelon®, as first-line treatment for Alzheimer's disease
22-Jan-2001 -
The National Institute for Clinical Excellence (NICE), a division of the National Health Service in the United Kingdom, has finalized an appraisal that recommends the use of
cholinesterase inhibitors, rivastigmine, donepezil and galantamine, for first-line treatment in Alzheimer's disease ...
Alzheimer's disease
clinical trials
inhibitors
+4